<?xml version="1.0" encoding="UTF-8"?>
<p>During the study, 29 subjects reported 60 AEs related to the study drug (
 <xref rid="t2-dddt-12-2381" ref-type="table">Table 2</xref>). Most AEs were related to pain and blood disorders, including back pain, neutropenia, and leukopenia. All AEs were mild in severity and none serious. At post-study period, subjects with AEs were followed up and all contactable subjects were confirmed to have fully recovered. In addition, no subjects in this study developed anti-filgrastim antibodies during hospital stay and at follow-up.
</p>
